实用肝脏病杂志2011，Vol.14Issue(3)：197-199,3.DOI:10.3969/j.issn.1672-5069.2011.03.014
恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周疗效观察
Efficacy of entecavir in the treatment of patients with chronic hepatitis B and cirrhosis
张馨 1高蕾 1王银玲 1汪茂荣1
作者信息
- 1. 210002,南京市,解放军第81医院全军肝病中心
- 折叠
摘要
Abstract
Objective To investigate the effectacy of entecavir in the treatment of patients with chronic hepatitis B and cirrhosis.Methods Thirty-four patients with chronic hepatitis B and twenty-four patients with HBV-indnced liver cirrhosis took ETV 0.5mg/d orally for 96 weeks.Results In the CHB group,the rates of HBV DNA negativity at week 12,24,48 and 96 were 61.76％ (21/34), 82.35％ (28/34) ,94.12％ (32/34) and 94.12％ (32/34, P＜0.05), respectively; and in the LC group, they were 72.73％ (16/22), 81.82％ (18/22), 81.82％ (18/22) and 90.91％ (20/22, P＜0.05), respectively;At week 12, the levels of serum ALT were significantly decreased (P＜0.05).No side effect was observed in the patients during treatmnent.Conclusion ETV is effective and safe in treatment of patients with chronic hepatitis B and with HBV-induced liver cirrhosis.关键词
乙型肝炎/恩替卡韦/肝硬化/治疗引用本文复制引用
张馨,高蕾,王银玲,汪茂荣..恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周疗效观察[J].实用肝脏病杂志,2011,14(3):197-199,3.
